RARE Stock Climbs This Week!Ultragenyx Pharmaceutical, Inc.BATS:RAREKalaGhaziUltragenyx Pharmaceutical (RARE) is rallying this week as investors digest last Thursday's FDA approval of Fayuvi and a round of higher Wall Street price targets, even as the company awaits future catalysts including shipments of its two recently approved therapies and results from a Wilson disease trial. Shares jumped about 13% on September 17 and continued the rally this week. That move represents a rebound from the $12.73 low hit earlier this month, though the stock remains far below its pre-crash level near $26. The recovery reflects a market that is beginning to look past the company's recent clinical setback and toward a series of nearer-term commercial and regulatory milestones that could reshape the investment case. First Treatment for Sanfilippo Syndrome Type A On September 17, the FDA granted full approval to Fayuvi, the first therapy for Sanfilippo syndrome Type A, a rare and fatal childhood brain disease. The one-time gene therapy is intended for children who still have some developmental function. That detail matters because Sanfilippo syndrome Type A is a progressive disorder, and patients who have already lost significant developmental function may not be eligible for the treatment. By targeting children earlier in the disease course, Fayuvi aims to preserve as much cognitive and physical function as possible. Ultragenyx also received a Priority Review Voucher with the decision. Priority Review Vouchers are transferable assets that can be sold to other companies, allowing the buyer to expedite FDA review of a future application. The product is expected to ship to specialized treatment centers in 30 to 60 days, at a list price of about $3.95 million. That price point places Fayuvi among the most expensive one-time therapies in the market, reflecting both the rarity of the disease and the complexity of developing and manufacturing a gene therapy. The approval is Ultragenyx's second gene therapy clearance in a month, after Genglycos was approved in August. Having two gene therapy approvals in such a short window is a significant operational achievement for the company. It demonstrates that Ultragenyx can not only develop these therapies but also navigate the FDA review process successfully—twice—in a compressed timeframe. What Comes Next Near-term focus now shifts from the FDA approval to execution. Investors will be watching several specific events: The first Fayuvi and Genglycos shipments: The transition from approval to commercial launch is a critical test. Manufacturing, distribution, and reimbursement all need to work smoothly for the launches to gain traction. Any sale of the two vouchers it received with the two therapy approvals: Ultragenyx has said it plans to sell the Priority Review Vouchers for cash. The vouchers sell for about $200 million each, giving Ultragenyx the possibility of $400 million in cash. That would be a meaningful infusion of non-dilutive capital. Fourth-quarter data from UX701 in Wilson disease: This is a pivotal readout that could reopen the growth narrative. November earnings for launch details and cost cuts: The company has said it will discontinue the Angelman program and cut costs. Investors will want specifics on how much is being saved and how those savings are being redeployed. The potential $400 million from voucher sales is particularly important. For a company with a market cap of roughly $1.4 billion, that kind of cash would substantially strengthen the balance sheet. It could fund the commercial launches, support ongoing research, and reduce the need to raise capital through equity or debt. In a sector where financing can be difficult, non-dilutive cash is especially valuable. Wilson Disease Data Could Be a Key Catalyst Further, Ultragenyx is slated to announce data from its pivotal study of UX701 in Wilson disease in the fourth quarter. Positive higher-dose data would reopen a growth narrative after the Angelman miss. Wilson disease is a rare genetic disorder that causes copper to accumulate in the body, potentially leading to liver damage, neurological problems, and other serious complications. A successful therapy in this indication would address a significant unmet need and could represent a substantial commercial opportunity. The Wilson disease readout is important for another reason: it would give investors a new reason to believe in the company's pipeline after the Angelman disappointment. If the higher-dose data are positive, it would suggest that Ultragenyx's platform can produce successful therapies beyond the two recently approved products. That could shift the narrative from a story about a single setback to a story about a company with multiple shots on goal. Angelman Setback Still Defines the Chart On September 2, Ultragenyx said its late-stage Aspire trial of GTX-102 in Angelman syndrome missed both its main goals. Shares fell about 44% the next day. The company has since said it will discontinue the program and cut costs. That miss erased what many investors had treated as the company's clearest path to a much larger market. The magnitude of the decline—44% in a single day—shows how much of the stock's value had been tied to the Angelman program. Angelman syndrome is a rare neurogenetic disorder, and a successful treatment would have addressed a significant unmet need. Investors had viewed GTX-102 as the company's most promising pipeline asset, and its failure removed a major source of expected future revenue. The decision to discontinue the program and cut costs is a necessary response. It preserves capital and allows management to focus resources on the approved gene therapies and other pipeline candidates. But it also means the company must now rely on Fayuvi, Genglycos, UX701, and any earlier-stage assets to drive future growth. That is a narrower base than investors had hoped for before the Angelman data. Analysts Lift Targets, With Caveats Earlier this week, several analysts raised their price targets on RARE, though not all were equally enthusiastic: Barclays raised its target to $35 from $32 on RARE and kept an Overweight rating. The Angelman miss hurt sentiment, the firm said, but Ultragenyx's roughly $1.4 billion market cap undervalues the existing business and the new gene therapy launches. That argument suggests Barclays sees the selloff as overdone and believes the market is not fully appreciating the commercial potential of Fayuvi and Genglycos. Morgan Stanley raised its target to $20 from $18 and kept Equal Weight. Fayuvi's full approval is "a positive," the firm said, but it wants to see actual launch numbers and a reset of the pipeline. That is a more measured view. Morgan Stanley appears to be taking a wait-and-see approach, acknowledging the approval as a step forward while wanting evidence that the launches are generating real revenue and that the pipeline can produce additional wins. Cantor Fitzgerald lifted its target to $39 from $33 and kept Overweight, calling Fayuvi a "much-needed win." The phrase "much-needed" reflects the context: after the Angelman failure, the company needed a positive catalyst to restore confidence. Cantor's target implies significant upside from current levels, suggesting the firm sees substantial value in the approved therapies and remaining pipeline. The range of targets—from $20 at Morgan Stanley to $39 at Cantor Fitzgerald—illustrates the uncertainty surrounding the stock. Bulls see a company with two approved gene therapies, potential voucher cash, and a pipeline that could deliver more wins. Bears or more cautious analysts want to see commercial execution before raising their expectations. How Did RARE Retail Traders React? On Stocktwits, retail sentiment around RARE stock stayed in 'extremely bullish' territory over the past 24 hours, while message volume remained 'extremely high.' That combination of strong bullish sentiment and high engagement suggests retail investors are paying close attention to the stock and are optimistic about the recent developments. Retail sentiment can be a useful indicator of momentum, but it is not always a reliable predictor of future performance. High bullish sentiment can sometimes precede a pullback if expectations become too elevated. Conversely, it can also reflect genuine enthusiasm about a company's prospects. In RARE's case, the bullishness appears tied to the FDA approval, the prospect of voucher sales, and the potential for positive Wilson disease data. What to Watch Next Several key events and trends will shape the stock's trajectory: Fayuvi and Genglycos launch execution: How quickly do shipments reach treatment centers, and how smoothly does reimbursement proceed? Voucher sales: Does Ultragenyx successfully sell both vouchers, and at what price? Wilson disease data: Do the higher-dose UX701 results in the fourth quarter support further development? November earnings: What details does management provide on launch progress, cost cuts, and cash runway? Pipeline reset: What does the company's remaining pipeline look like after the Angelman discontinuation? Analyst revisions: Do more firms raise targets or upgrade the stock, or do cautious views persist? Cash position: How much cash does the company have after the voucher sales and cost cuts, and how long will it last? Competitive landscape: Are other companies developing therapies for Sanfilippo syndrome, MPS disorders, or Wilson disease? Investor Takeaway Ultragenyx is in the early stages of a transition from a clinical-stage story to a commercial-stage story. The FDA approval of Fayuvi—and the earlier approval of Genglycos—gives the company two marketed gene therapies and the potential for up to $400 million in cash from voucher sales. The Wilson disease data in the fourth quarter could provide another catalyst. But the Angelman failure remains a significant setback, and the company will need to demonstrate that it can execute commercially and advance its remaining pipeline. The stock's rally this week suggests investors are willing to look past the Angelman miss and focus on the opportunities ahead. Analysts have raised their targets, though with varying degrees of caution. Retail sentiment is extremely bullish. The next few months will be critical: launch execution, voucher sales, Wilson disease data, and the November earnings report will all provide evidence about whether the recovery rally can be sustained. For now, RARE remains a high-risk, high-reward story with multiple near-term catalysts that could move the stock in either direction.